Tenderwize
Zurück zur Suche

Open-house rebate agreement for Rasagilin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rasagilin, ATC N04BD02

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

48 / 100

Risikofaktoren

Paper submissions are only timely if the complete original documents arrive by the 10th of the month after prior transm...

The notice requires a signed declaration of reliability and indicates that only pharmaceutical companies can contract;...

Submission deadline in 8 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house rebate agreements for Rasagilin, ATC N04BD02.
  • Supply of pharmaceutical products under fixed, pre-defined contract terms.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Rasagilin (ATC N04BD02) offered by AOK Bayern. It is not a competitive award procedure: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract period runs from 01.11.2024 to 31.10.2026, with the latest possible contract conclusion on 05.09.2026. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents.

Risiken

Paper submissions are only timely if the complete original documents arrive by the 10th of the month after prior transm...

The notice requires a signed declaration of reliability and indicates that only pharmaceutical companies can contract;...

Submission deadline in 8 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The signatory's authority must be evidenced by the commercial register extract, otherwise a power of attorney must be provided.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Rasagilin

Single lot covering non-exclusive open-house rebate agreements for the medicinal product Rasagilin, ATC N04BD02. The lot is for pharmaceutical products (CPV 33600000) and performance is in Germany, specifically DE212. The notice text indicates the contract terms are fixed in advance and not individually negotiable.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2024 - Oct 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 05, 2026

Vergabedetails

Veröffentlichungsdatum
16 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
556500-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30